BioUtah, Life Sciences Innovators Take Stage at Legislature’s Interim Meeting
September 21, 2023
The Utah Life Sciences Innovation Caucus, a bipartisan group of state legislators working to advance our life sciences industry and improving healthcare, hosted a lunch for all legislators during the September 18 interim meeting held in St. George. The caucus event, attended by all legislators from the House and Senate as well as staff provided an opportunity for lawmakers to learn not only about the industry in general in Utah, but also its impact in Southern Utah. The event was kicked off by comments about the industry and the Caucus by Senate President Stuart Adams, House Majority Whip, Jefferson Moss and Senate Majority Whip, Ann Millner.
Dr. Howard McLeod and Associate Dean, Aaron Davis, presented how funding from the legislature was key to establishing the Center for Precision Medicine and Functional Genomics making Utah Tech a center of excellence in this field. Their presentation was followed by a panel of eight life sciences companies from the St. George area moderated by Kelvyn Cullimore, CEO of BioUtah.
Panelists included:
- Lincoln Nadauld, Culmination Bio
- Mark Gubler, Deseret Labs
- Greg Prince, Soft Cell Bio Labs
- Cody Ballantyne, Forward Motion
- Seth Campbell, BioFi
- Jeremy Bradley, CathTip
- Scott Madsen, Birch OS
- Whitney Mason, Intermountain Precision Genomics
“The Life Sciences Innovation Caucus has become a unique opportunity to educate lawmakers about the important work we do and the contributions our industry makes to driving the Utah economy,” said Cullimore.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology